An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study is an 8-week open-label trial testing oxytocin nasal spray (Syntocinon) as a
treatment for social impairment in adolescents with autism spectrum disorders (ASD). We
hypothesize that oxytocin nasal spray will be safe, tolerable, and effective in improving the
core symptoms of autism spectrum disorders in adolescents ages 11-17.